Central European Cooperative Oncology Group
14
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
35.7%
5 terminated/withdrawn out of 14 trials
64.3%
-22.2% vs industry average
50%
7 trials in Phase 3/4
22%
2 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Role: lead
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Role: lead
Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
Role: collaborator
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
Role: lead
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Role: lead
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
Role: lead
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
Role: collaborator
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Role: lead
Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer
Role: lead
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
Role: lead
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Role: lead
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
Role: lead
An Open, Randomized, Multicentre, Phase II Pilot Study
Role: lead
Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
Role: lead
All 14 trials loaded